YOSI

Young Ophthalmologists Society of India is a vibrant society for ophthalmology trainees, residents & young ophthalmologists of India. We grow together!

[YOSI @YOSI_India]

AIOS YOSI Writing Competition 2023 We invite entries for the Writing competition 2023 — click on this link & fill the form for submitting your entries ! Exciting prizes for the most talented YOs
https://t.co/DvHdVfYbvu

[YOSI @YOSI_India]

The Young Ophthalmologists Society of India (YOSI) presents the **YOSI Writing Competition 2025**! Let your words flow like a river on the topic: *"Does artificial intelligence make me a better ophthalmologist? Why? If not, why not?"*
https://t.co/SuZHAUmMVB

[YOSI @YOSI_India]

Congratulations to winners of AIOS YOSI Writing competition 2023

[YOSI @YOSI_India]

Join us for this interesting session discussing Teprotumumab in Thyroid Eye Disease on *14th July, 2022, 8.30 PM onwards* Register using the link - https://t.co/wzCB31eVat

[YOSI @YOSI_India]

We welcome entries for AIOS YOSI Writing Competition 2022 !
https://t.co/deZTSc1cLS

[Ram Gopal Varma @RGVzoomin]

Though I only drink Vodka, I made the Goddess Maisamma drink Whisky 😃

[YOSI @YOSI_India]

YOSI JOURNAL CLUB - Session 3 - discussion on the FACT Trial by Team YOSI & invited panelists - Femtosecond Laser Assisted Cataract Surg... https://t.co/Z4Cl4eREA7 via @YouTube

[YOSI @YOSI_India]

*Watch the 4th session of YOSI Journal Club*
10th June

Non-malignant conjunctival epithelial masses with ocular surface squamous neoplasia-like optical coherence tomography features. Int Ophthalmol. 2021;41(5):1827-1834.
https://t.co/tdoyR3kCv1

[YOSI @YOSI_India]

Nevus of Ota (Oculodermal Melonocytosis) by Dr. Rinal Pandit MS, FMRF, FICO Consultant Ophthalmologist & Glaucoma Surgeon at Choithram Netralaya, Indore. https://t.co/zcecufZqIu

[Sagnik Sen, M.D. @riksag]

Intraocular bevacizumab injections are vision-saving for a lot of patients. However, its usage has been marred with controversies and has come under surveillance under the DCGI regarding occurrence of endophthalmitis.
https://t.co/WwtdpNBX9f

[Sagnik Sen, M.D. @riksag]

In this multicentric study, we describe the largest cohort of

[Sagnik Sen, M.D. @riksag]

patients who received "pre-packaged bevacizumab" and the incidence of endophthalmitis in them. The rate of endophthalmitis is no different from the international rate with other anti-VEGFs like Lucentis or Eylea.
We hope this study will further help legislators and policy makers

[Sagnik Sen, M.D. @riksag]

understand the safety of the drug and the approval of the same for wider intraocular usage, moreso since it is the cheapest anti-VEGF available. #clinicalresearch #clinicaltrials #ophthalmology #ophthalmologyresident #retina #retinaldisease #retinaspecialist #retinasurgery

[YOSI @YOSI_India]

https://t.co/dyV9Wu0D5m

YOSI Journal Club - 1st session:
ARTEMIS 1 Study well presented by Junior Resident & Finer points of the research paper discussed by panel of Research & subject experts

[YOSI @YOSI_India]

@NatEyeInstitute @ARVOinfo But

[YOSI @YOSI_India]

@DrLorraineEyeMD Hi ! Do u need responses from India also ?

[YOSI @YOSI_India]

https://t.co/OK4wWgVkMU

Pearls about congenital glaucoma & case presentation

[YOSI @YOSI_India]

Join team YOSI for an interesting discussion on Congenital Glaucoma

[YOSI @YOSI_India]

Such a beautiful analogy to explain about keratoplasty !!

[YOSI @YOSI_India]

https://t.co/GbNXkqFWiA

YOSI cornea CME